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86 Poster Session-IWhen in endothelial cell culture conditions, the blast cells differen-
tiated to endothelial cells which had the ability to take up Dil-
Ac-LDL and formed complex vascular networks in Matrigel.
We concluded that: 1) hemangioblast exist transiently in early
embryonic development and can form single cell-derived colonies;
2) differentiation of hemangioblasts can be tracked by the use of
chosen molecular markers; 3) blast colonies consist of cells having
properties of endothelial or hematopoietic precursors, 4) blast cells
can be potentially used in regenerative medicine due to their low
immunostimulatory potential.
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NASAL EPITHELIAL CELLS OF DONOR ORIGIN AFTER ALLOGENEIC HCT:
RESULT OF STEM-CELL PLASTICITY, CELL-FUSION OR TRANSFER OF
EPITHELIAL CELL PRECURSORS WITH THE GRAFT?
Khan, F., Sy, S., Louie, P., Smith, M., Chernos, J., Lee, R., Berka, N.,
Sinclair, G., Leigh, R., Proud, D., Russell, J., Storek, J. University of Cal-
gary, Calgary, AB, Canada
Background: Epithelial cells (ECs) are generally believed to orig-
inate from epithelial stem cells and not from hematopoietic stem
cells (HSCs). However, detection of donor-type myocytes, neurons
and skin, liver, lung or intestinal epithelial cells after allogeneic
HCT (using XY-FISH and sex-mismatched donor-recipient pairs)
has suggested that HSCs may carry a degree of developmental
plasticity. This is controversial given artifacts of the XY-FISH or
the possibility of hematopoietic-EC cell fusion. Alternatively,
donor-type ECs post-transplant could originate from ECs or their
precursors transferred with the graft. The goal of this study was to
determine whether donor origin nasal ECs exist in HCT recipients,
and if so, then the underlying mechanism.
Methods: We collected nasal scrapings and whole blood from 35
HCT survivors, either early (2–3 months, n5 15) or late (4–22 years,
n5 20) post-transplant. Bone marrow was grafted in 15 of the 20 late
post-transplant patients whereas filgrastim-mobilized blood stem
cells were grafted in all 15 early and 5 late post-transplant patients.
To avoid the limitations of XY-FISH, chimerism of the ECs was de-
termined as: Nasal cells were stained with cytokeratin (CK) and
CD45 antibodies. True ECs (CK1CD45_) were laser captured.
DNA extracted from the captured ECs and blood leukocytes was
PCR amplified for a panel of 15 autosomal STR markers and an
XY-differentiating locus (ABI-Identifiler). In addition, a combina-
tion of immunofluorescence staining for CK and FISH for two auto-
somes was used in 10 patients to assess cell fusion. Epithelial cell
precursors in 8 graft specimens were searched by using magnetic sep-
aration with CD36 microbeads and staining with CK.
Results: In all 35 HCT survivors, ECs of donor origin were iden-
tified accounting for 2.2% to 12.3% (median 6.2 %) of the nasal ECs.
The percentage appeared to be2-fold higher late posttransplant in
marrow compared to blood stem cell recipients and was similar in
blood stem cell recipients early and late posttransplant. None of
the nasal ECs in 10 HCT survivors exhibited the presence of cell fu-
sion. Epithelial cells/epithelial cell precursors (CD361CK1) were
found in each of the 8 graft specimens.
Conclusion: Donor origin nasal ECs were identified even with
a method that obviates the artifacts of XY-FISH. The underlying
mechanism appears to be trans-differentiation of HSCs into ECs
or the transfer of ECs (or their precursors) with the graft, but not
cell fusion.237
ISOLATION AND EXPANSION OF OLIGODENDROCYTES FROM THAWED,
CRYOPRESERVED HUMAN UMBLILICAL CORD BLOOD
Tracy, E.1, Gentry, T.2, Shoulars, K.1, Hughes, M.3, Kurtzberg, J.1
1Duke University, Durham, NC; 2Aldagen, Durham, NC; 3Columbia
University, NY, NY
While transplantation of unrelated umbilical cord blood (UCB)
halts the progression of neurological damage in children with lyso-
somal storage diseases (LSD), it does not necessarily reverse the
damage sustained before transplant. Isolation and expansion of cen-
tral nervous system progenitor cells from UCB has potential thera-
peutic application in treating these patients. We recently described
the reliable isolation and expansion of oligodendrocyte-like precur-
sor cells (OPC) from freshly collected, non-crypreserved UCB(Tracy et al. Cytotherapy. 2008, 3:1–8). We anticipate utilizing these
cells as adjuvant, targeted therapy to reduce the time to donor cell
correction/prevention of disease-induced CNS injury. This ap-
proach will require use of cyropreserved donor UCB. We now dem-
onstrate the feasibility of isolating and expanding OPCs from a series
of thawed, cryopreserved UCB units. Cryopreserved UCB units
were thawed using a standard protocol employed in clinical trans-
plantation. Mononuclear cells were isolated by either ficoll density
separation or centrifugation after a dextran-albumin wash. Fresh
UCB units underwent hetastarch depletion of red blood cells then
mononuclear cell isolation by ficoll density gradient separation.
Cells were plated at 3  10(6) cells/ml in media containing platelet
derived growth factor, neurotopin 3, vascular endothelial growth
factor, and triiodothyronine. All UCB unit cultures were trypsinized
at 21 days, counted, then characterized by flow cytometry after being
fixed, permeablized, and labeled with the following antibodies: anti-
oligidendrocyte marker 4 (O4), anti-oligidendrocyte marker 1 (O1),
anti-myelin basic protein (MBP). To examine phenotypic changes
over time, cultures from two units (one thawed, one fresh) were an-
alyzed weekly over 4 weeks. On flow cytometric analysis, 78% of
thawed UCB units yielded O4-expressing cells as at least 20% of to-
tal events compared with 95% of fresh UCB units.
Table 1: Characteristics of UCB-Derived Oligodendrocytes
Thawed UCB Units Fresh UCB UnitsTotal Units Cultured 27 19
Mean # mononuclear
cells plated/UCB Unit
3.03  10 (8) 1.53  10 (8)Final oligodendrocyte
cell count/UCB Unit8.41  10 (5) 3.41  10 (6)Units with O4 expression
.20% of total events21 (78%) 18 (95%)Events in gate as % total events 54.06 76.54
O4 expression (% of gated)
85.93 87.88
85.93 87.88O1 expression (% of gated) 89.84 88.40
MBP expression (% of gated) 28.87 30.51
Co-expression of MBP-O1
(% of gated)
26.67 30.50Average OPC yield per UCB unit was less for thawed units (8.41
10(5)) than fresh (3.41 10(6)). However, expression of O1, O4, and
MBP was similar. We also noted early expression of the preoligoden-
drocyte marker O4 by 1–2 weeks in culture, followed by expression
of mature oligodendrocyte markers O1 and MBP over 2–4 weeks.
Our results demonstrate that oligodendrocyte precursor cells can
be derived reliably from thawed, cryopreserved UCB units, and
suggest the feasibility of using these cells in human clinical trials.238
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) FOR RELAP-
SED, REFRACTORY MYELOID LEUKEMIA AND MDS USING CLOFARABINE
(CLO)6 FLUDARABINE (FLU) WITH IV BUSULFAN (BU) AS CONDITION-
ING THERAPY
Andersson, B.S.1, de Lima, M.1, Popat, U.1, Jones, R.B.1, Shpall, E.J.1,
Hosing, C.1, McAdams, P.L.1, Alousi, A.M.1, Kebriaei, P.1,
Champlin, R.E.1, Worth, L.L.3, Madden, T.L.3, Kazerooni, R.4 1UT
M.D. Anderson Cancer Center, Houston, TX;2,3,4
IV Bu/Flu is a safe conditioning regimen, but relapses still occur.
We decided to replace Flu with Clo to enhance the regimen antileu-
kemic effect. The immunosuppressive capacity of Clo is unknown,
and we gradually replaced Flu with Clo, aimed at retaining safety
while evaluating the engraftment-promoting capacity of Clo.
Methods: Patients were randomized to: Arm I: Clo:Flu 10:30 mg/
m2, Arm II 20:20 mg/m2, Arm III 30:10 mg/m2; Arm IV Clo 40 mg/
m2. The nucleoside analog(s) were/was infused over 1 hour daily4
days; Bu was infused over 3 hours (daily AUC of 6,000 mcMol-min6
10%), immediately after the nucleoside analog(s). 25 pts have been
enrolled, 22 are evaluable for engraftment and survival beyond day
100; 16 were males; median age was 46 yrs (6–59). 7 pts had CML
(BC: 1, first AP: 3, second AP: 2, and late first CP: 1). 18 patients
Poster Session-I 87had AML: 6 induction failures, 6 in refractory relapse, 3 in untreated
relapse, 1 had a second PR, 1 chemo-responsive MDS, 1 in high-risk
CR1 [cytogenetics (CG) -7/t(3;12)]. CG were favorable (n5 1), 8 in-
termediate, and 6 poor prognosis, and in 3 CG were unknown.
GVHD-prophylaxis: tacrolimus/mini-MTX, with rabbit-ATG
(Thymoglobulin) for unrelated/one Ag-mism. related donor trans-
plants.
Results: 1 patient died of pneumonia (day177), and 1 of liver
GVHD (day145) as only treatment-related deaths in the 1st 100
days. Main toxicity was mucositis grade 2–3 (50% of the pts). There
was no significant hepatic/neurologic toxicity. All 22 evaluable pts
engrafted (one progressed by day 130). T-cell chimerism studies
at day130 revealed that groups I1II (lower Clo doses; n 5 10)
had a median of 87% (17–100) donor (T-cell)-derived DNA, groups
III1IV (higher Clo-doses, n5 12) had a median of 100% range (64–
100) donor-DNA. By day1100 both cohorts had a median of 100%
donor-derived DNA, maintained beyond 6 mo. in all evaluable pts. 3
pts are too early; 10 pts have died: PD (5), GVHD 6 infection (4),
and pneumonia (1); 1 AML patient is alive after recurrence and 7
AML and 4 CML patients are alive in CR at a median F/up of 9
mos (4–21).
Conclusions: 1) Clo-Bu-based conditioning appears safe in high-
risk ML pts. 2) there should be no concern about the immunosup-
pressive capability of Clo in this setting 3) additional studies are war-
ranted to evaluate the antileukemic efficacy of this regimen.
Supported by NIH grants CA55164 and CA49639.Neutropenic
diet
Non-neutropenic
diet P
Age (years) 57 (18–76) 56 (18–78) 0.89
Male:Female 186:128 190:124 0.97
Allogeneic:Autologous 77:237 72:242 0.64
Diagnosis 0.91
Myeloma 163 165
NHL 57 64
AML 54 50
Other 40 39
Conditioning regimen 0.97
High-dose Melphalan 163 165
BEAM 45 42
Busulfan-fludarabine 32 33
Reduced-intensity 33 36
Median days to neutrophil
recovery
12 12 0.91
Positive cultures during
neutropenia
97 89 0.49
CoNS/MSSA/MRSA 1
miscellaneous gram-positive
32 33 1
C difficile 24 22 0.88
E faecium (VRE) 9 9 1
Non-VRE Enterococci 3 3 1
Gram-negative bacilli 15 9 0.21
S viridans 11 10 1
Fungus 4 3 1
Positive cultures after
resolution of neutropenia
48 20 \0.001
CoNS/MSSA/MRSA 1
miscellaneous gram-positive
21 9 0.028
C difficile 9 2 0.069
E faecium (VRE) 7 3 0.34
Gram-negative bacilli 8 4 0.38
S viridans 2 1 1
Fungus 1 1 1
VRE surveillance culture
positivity acquired during
hospitalization
56 31 \0.004SUPPORTIVE CARE
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A RANDOMIZED, CONTROLLED TRIAL OF GRAFT-VERSUS-HOST DISEASE
(GVHD) PROPHYLAXIS COMPARING TACROLIMUS AND MYCOPHENO-
LATE MOFETIL TO TACROLIMUS AND METHOTREXATE: ANALYSIS OF
GVHD, RELAPSE AND SURVIVAL
Perkins, J.1, Alsina, M.1, Anasetti, C.1, Ayala, E.1, Fernandez, H.1,
Kharfan-Dabaja, M.1, Ochoa-Bayona, L.1, Perez, L.1,
Raychaudhuri, J.1, Sullivan, D.1, Kim, J.2, Schell, M.2, Field, T.1 1Mof-
fitt Cancer Center, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL
We conducted a single institution, randomized, controlled trial
comparing tacrolimus 1 MTX (TAC/MTX) to tacrolimus 1
MMF (TAC/MMF). Eligible patients (pts) were to receive T-replete
peripheral blood HCT from 10/10 or 9/10 HLA matched donors.
Randomization was stratified based on conditioning regimen inten-
sity. 92 pts were randomized, 45 to TAC/MMF and 47 to TAC/
MTX and were all included in the intent-to-treat (ITT) analysis.
Two pts were not transplanted and one pt withdrew consent prior
to transplant. These pts were excluded in the modified ITT
(MITT) analysis. Pts received TAC 0.03 mg/kg/24hr as a continuous
IV infusion beginning day -3 with doses adjusted to maintain whole
blood levels of 5–15ng/ml. Pts were converted to PO therapy and ta-
pered after 6 months. MTX was given IV at doses of 15mg/m2 day
11 and 10mg/m2 on days 13, 16 and 111. MMF was dosed at 15
mg/kg every 12 hours (up to 3g/d) IV beginning day 0, switched to
PO and continued for 12 months. Acute GVHD (aGVHD) was
graded weekly by standard criteria; chronic GVHD (cGVHD) was
scored monthly based on NIH consensus criteria. The groups
were balanced with respect to age, diagnosis, disease risk, recipi-
ent/donor CMV status, conditioning regimen, donor type and rela-
tion. The cumulative incidences of grade 2–4 and 3–4 aGVHD were
79% and 4% in the TAC/MTX arm and 76% and 14% in the TAC/
MMF arm (MITT; p 5 0.84 and 0.1, respectively). The cumulative
incidence of moderate or severe cGVHD at 6 months was 22% in the
TAC/MTX arm and 26% in the TAC/MMF arm (MITT; p5 0.88).
By ITT analysis, the cumulative incidence of non-relapse mortality
suggested an early difference in favor of TAC/MTX, but at 2 years
it was 28% for TAC/MTX arm compared to 32% for the TAC/
MMF arm (p 5 0.41). The cumulative incidence of relapse was
33% in TAC/MTX arm compared to 18% for the TAC/MMF pts
(p 5 0.06). Overall survival was similar between groups (p 5 0.76;
62% TAC/MTX vs. 66% TAC/MMF at 1 year). We conclude
that MMF was no better than MTX in preventing GVHD and
may perhaps be less effective in preventing more severe forms ofaGVHD. Given the direction of effect we observed in severe
aGVHD, it is unlikely that a larger trial would show benefit for
this endpoint. There was a strong suggestion that relapse was
more frequent after MTX than MMF. The beneficial effect of
MMF on relapse was offset by the early increase in nonrelapse mor-
tality, so that overall survival was unaffected.240
QUESTIONING THE ROLE OF A NEUTROPENIC DIET IN HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Trifilio, S., Pi, J., Holmes Gobel, B., Giel, M., Fishman, M., Masino, K.,
Lucier, E., Korenaga, Y., Mehta, J. Northwestern Memorial Hospital,
Chicago, IL
Neutropenic diets (ND) were developed to decrease gut-derived
infections and are widely used. After finding that there were no clin-
ical trials supporting their use, we discontinued ND in HSCT in late
2006. Our ND excluded fresh fruits and vegetables as well as black
pepper, sushi, deli meats, raw milk products, soft cheeses, raw honey,
miso, and yeast. It was replaced by a modified general diet (Non-
ND) that permits black pepper, fresh fruits and vegetables, and
homemade freshly squeezed juice - but excludes raw tomatoes.
The other restrictions remain. 648 consecutive hospitalized patients
were studied; 314 on ND and 314 after ND discontinuation (non-
ND). All infections occurring during the first hospital stay were
analyzed. All patients received ciprofloxacin 500 mg twice a day,
fluconazole 200 mg daily (autograft) or voriconazole 200 mg twice
daily (allograft), and acyclovir/valacyclovir. The documented infec-
tions included in the analysis comprised positive blood, urine
(.100,000 organisms), BAL, stool, or wound cultures, and clostrid-
ium difficile. As the table shows, there were no differences between
